Table 2.

Comparison of clinical features among patients with idiopathic membranous nephropathy with anti-THSD7A antibodies, anti-PLA2R antibodies, and neither of them (double-negative)

CharacteristicTHSD7A-Associated (n=12)PLA2R-Associated (n=510)Double-Negative (n=49)P Value
Age, yr52±1852±1453±130.74
Sex (male/female)8/4291/21927/220.77
Urinary protein, g/24 h5 (4–12)4 (3–7)4 (2–5)0.15
Albumin, g/L25±628±824±100.21
Microscopic hematuria, n (%)7 (58)242 (48)27 (55)0.46
Serum creatinine, mg/dl0.86 (0.60–1.07)0.78 (0.62–0.98)0.62 (0.54–0.83)0.23
Declined eGFR (<60ml/min per 1.73 m2), n (%)1 (8)34 (7)6 (12)0.35
Hemoglobin, g/dl14±313±213±20.57
Cholesterol, mg/dl309±116309±116309±1550.93
Hypertension, n (%)4 (33)184 (36)13 (27)0.41
Intensity of IgG staining, median (range)3+ (2,3)3+ (2,3)3+ (2,3)0.30
Intensity of C3 staining, median (range)1+ (1,2)1+ (0–1)1+ (0–1)0.10
Total no. of glomeruli24±1226±1325±110.61
Churg stage of membranous nephropathy, n (%)0.19
 I6 (50)194 (38)21 (43)
 II6 (50)312 (61)26 (53)
 III04 (1)2 (1)
Global sclerosis, %0 (0–2)1 (0.25–1.0)1 (0–2)0.05
TA/IF, median (range)1 (0–1)1 (0–1)1 (0–1)0.51
Immunosuppressive therapy, n (%)6 (50)372 (73)38 (78)0.16
Complete or partial remission, n (%)11 (92)404 (79)38 (78)0.55
Time to remission, mo9 (5–13)12 (6–19)9 (5–14)0.14
Relapse, n %3 (25)124 (24)17 (35)0.28
Kidney dysfunction during follow-up, n (%)1 (8)67 (13)7 (14)0.86
Follow-up time, mo27 (19–34)36 (25–55)35 (24–65)0.06
  • eGFR was calculated using the Modification of Diet in Renal Disease Study equation adjusted for Chinese populations (24): eGFR = 175 × (plasma creatinine)−1.234 × age−0.179 × 0.79 (if female). Semiquantitative scoring is graded according to the percentage of interstitial area involved: 0, 0%; 1, 5%–25%; 2, 25%–50%; 3, >50%. Kidney dysfunction was defined as eGFR decreased >30% from baseline and below 60 ml/min per 1.73 m2. TA, tubular atrophy; IF, interstitial fibrosis.